(Q40874854)

24 September 2017

1 reference

title

Inactivation of viruses in blood and plasma products (English)

1 reference

24 September 2017

Suomela H

1

1 reference

24 September 2017

publication date

1 January 1993

1 reference

Transfusion Medicine Reviews

24 September 2017

published in

1 reference

24 September 2017

volume

7

1 reference

24 September 2017

issue

1

1 reference

24 September 2017

page(s)

42-57

1 reference

Infectious complications of blood transfusion

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Antibodies to hepatitis B core antigen and the infectivity of the blood supply. Scientific Section Coordinating Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Controversies in transfusion medicine. Alanine aminotransferase screening of blood donors: con

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Alanine aminotransferase, gamma-glutamyltransferase, antibodies to hepatitis B core antigen and antibodies to hepatitis C virus in blood donor screening. A prospective study in Finland

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

1 reference

7 January 2021

Preparation and properties of a therapeutic factor IX concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Removal of hepatitis B virus from a concentrate of coagulation factors II, VII, IX and X by hydrophobic interaction chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Virucidal treatment of clotting factor concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Virus inactivation by addition of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

A novel method for removal of human immunodeficiency virus: filtration with porous polymeric membranes

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Validatable virus removal from protein solutions

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Acute hepatitis B infection after treatment with heat-inactivated factor VIII concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Strategies to produce virus-safe blood derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Virus inactivation by heat treatment of lyophilized coagulation factor concentrates.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

The development of the technology and capacity for the production of factor VIII for the treatment of hemophilia A.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Prospective study of hepatitis after factor VIII concentrate exposed to hot vapour

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Low risk of viral infection after administration of vapor-heated factor VIII concentrate. International Investigator Group

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Wet heating for safer factor VIII concentrate?

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Virus safety of solvent/detergent-treated antihaemophilic factor concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Tri(n-butyl) phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Photochemical decontamination of blood components containing hepatitis B and non-A, non-B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Photodynamic inactivation of animal viruses: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Photodynamic inactivation of simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Development of a model to demonstrate photosensitizer-mediated viral inactivation in blood

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Inactivation of viruses in blood with aluminum phthalocyanine derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Inactivation of lipid-enveloped viruses in proteins by caprylate

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Inactivation and stability of viral diagnostic reagents treated by gamma radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Posttransfusion cytomegalovirus infection in neonates: role of saline-washed red blood cells

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Reducing the Risk for Transfusion-transmitted Cytomegalovirus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Serum ALT levels in patients with primary hypogammaglobulinaemia receiving replacement therapy with intravenous immunoglobulin or fresh frozen plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Safety of Intravenous Immunoglobulin Preparations: A Prospective Multicenter Study to Exclude the Risk of Non-A, Non-B Hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Transmission of non-A, non-B hepatitis by pH4-treated intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Virus inactivation during intravenous immunoglobulin production

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Safety of intravenous immunoglobulin for treatment of auto-immune thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Long-term safety and tolerability of intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Prospective Study on the Hepatitis Safety of Intravenous Immunoglobulin, pH 4.25

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Virus inactivation during production of intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2893%2970032-2

7 January 2021

10.1016/S0887-7963(93)70032-2

Identifiers

DOI

0 references

1 reference